Guideline recommended heart failure therapy was well-established with 413 (93.2%) patients on betablocker, 414 (93.5%) patients receiving renin–angiotensin system inhibitors (RASi) [angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), or angiotensin receptor-neprilysin inhibitor (ARNi)], and 318 (71.8%) patients were on a mineralocorticoid-receptor antagonist (MRA). This evidence concerns the gene NR3C2 and heart failure.